Krystal Biotech (KRYS) Gains from Sales and Divestitures (2018)
Krystal Biotech's (KRYS) quarterly Gains from Sales and Divestitures came in at $10606.0 in Q3 2018, down 66.67% quarter-over-quarter from $31818.0 in Q1 2018.
Krystal Biotech (KRYS) Gains from Sales and Divestitures (2018) Analysis & Trends
Krystal Biotech has disclosed Gains from Sales and Divestitures across 1 years of filings, most recently posting $10606.0 for Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Krystal Biotech | 10.23 Bn | 9.41 Bn | 110.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 10,606.00 |
| Sep 30, 2018 | 10,606.00 |
| Mar 31, 2018 | 31,818.00 |
| Mar 31, 2018 | 31,818.00 |